INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
Public company

RVMDRevolution Medicines, Inc.

CIK 0001628171

EDGAR filingsOpen in network
Disclosed transactions35
Buys / sells0 / 27
Max Insider Score34
Connections7with evidence

RVMD · disclosed activity on price

Disclosed transactions

ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
5
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M$353K
6,000 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

Verified connections

  • In industryevidence
    Pharmaceuticals, devices & health servicesSEC SIC 2836 · Biological Products, (No Diagnostic Substances) · Nov 4, 2026
  • ← Insider ofevidence
    Anderson Elizabeth MDirector · Sep 24, 2026
  • ← Insider ofevidence
    Sandler Alan B.Chief Development Officer · Sep 18, 2026
  • ← Insider ofevidence
    Anders JackChief Financial Officer · Sep 18, 2026
19
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL
$244K
1,199 sh
Sep 29, 2026
Oct 1, 2026
traded Sep 29, 2026
+2d
SEC FORM 4

Evidence

19
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$203K
1,000 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

22
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$325K
1,609 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

22
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$442K
2,200 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

0
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M—
6,000 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

19
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$62K
301 sh
Sep 29, 2026Oct 1, 2026
traded Sep 29, 2026
+2dSEC FORM 4

Evidence

19
CJ
Cislini JeffSVP & General Counsel
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$159K
765 sh
Sep 25, 2026Sep 29, 2026
traded Sep 25, 2026
+4dSEC FORM 4

Evidence

16
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$117K
587 sh
Sep 24, 2026Sep 28, 2026
traded Sep 24, 2026
+4dSEC FORM 4

Evidence

0
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M$105K
3,121 sh
Sep 25, 2026Sep 28, 2026
traded Sep 25, 2026
+3dSEC FORM 4

Evidence

23
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$626K
3,121 sh
Sep 25, 2026Sep 28, 2026
traded Sep 25, 2026
+3dSEC FORM 4

Evidence

0
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M—
3,121 sh
Sep 25, 2026Sep 28, 2026
traded Sep 25, 2026
+3dSEC FORM 4

Evidence

34
AM
Anderson Elizabeth MDirector
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$960K
4,985 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

27
AM
Anderson Elizabeth MDirector
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$175K
910 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

11
AM
Anderson Elizabeth MDirector
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M$5,678
5,070 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

34
AM
Anderson Elizabeth MDirector
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$512K
2,648 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

34
AM
Anderson Elizabeth MDirector
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$292K
1,500 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

20
AM
Anderson Elizabeth MDirector
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$20K
100 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

0
AM
Anderson Elizabeth MDirector
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M—
5,070 sh
Sep 22, 2026Sep 24, 2026
traded Sep 22, 2026
+2dSEC FORM 4

Evidence

19
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$347K
1,764 sh
Sep 18, 2026Sep 22, 2026
traded Sep 18, 2026
+4dSEC FORM 4

Evidence

26
AJ
Anders JackChief Financial Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$796K
3,992 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

16
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$5,266
27 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

20
AJ
Anders JackChief Financial Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$12K
61 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

23
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$67K
336 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

20
SB
Sandler Alan B.Chief Development Officer
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$975
5 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

30
CJ
Cislini JeffSVP & General Counsel
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$660K
3,314 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

20
CJ
Cislini JeffSVP & General Counsel
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$10K
52 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

22
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$348K
1,747 sh
Sep 16, 2026Sep 18, 2026
traded Sep 16, 2026
+2dSEC FORM 4

Evidence

9
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M$315K
9,363 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

33
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$1.22M
6,019 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

33
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$1.13M
5,530 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

30
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$496K
2,420 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

23
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$243K
1,179 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

23
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Open-market sale · 10b5-1 plan
SELL$62K
300 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

3
MA
Mancini AnthonySee Remarks
RVMDRevolution Medicines, Inc.
Option exercise · 10b5-1 plan
M—
9,363 sh
Sep 10, 2026Sep 14, 2026
traded Sep 10, 2026
+4dSEC FORM 4

Evidence

  • ← Insider ofevidence
    Cislini JeffSVP & General Counsel · Sep 18, 2026
  • ← Insider ofevidence
    Mancini AnthonySee Remarks · Sep 14, 2026
  • ← Holdsevidence
    Duquesne Family Office LLC1.4% of reported portfolio · Aug 14, 2026